Twist Bioscience (NASDAQ:TWST) Stock Price Down 4.4%

Twist Bioscience Co. (NASDAQ:TWST)’s share price dropped 4.4% on Tuesday . The stock traded as low as $27.90 and last traded at $27.95. Approximately 98,884 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 907,806 shares. The stock had previously closed at $29.24.

Wall Street Analyst Weigh In

TWST has been the topic of several research analyst reports. Scotiabank boosted their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 5th. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and upped their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Finally, Barclays decreased their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th.

Twist Bioscience Trading Down 0.1 %

The firm’s fifty day moving average is $35.85 and its 200 day moving average is $29.94.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to the consensus estimate of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The firm’s revenue was up 31.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.74) EPS. On average, equities analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,132 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $37,061.68. Following the transaction, the chief executive officer now directly owns 514,149 shares in the company, valued at approximately $16,833,238.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the sale, the chief executive officer now owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the sale, the chief executive officer now directly owns 514,149 shares of the company’s stock, valued at approximately $16,833,238.26. The disclosure for this sale can be found here. Insiders have sold 11,037 shares of company stock worth $384,092 in the last three months. Corporate insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of TWST. Envestnet Asset Management Inc. lifted its position in Twist Bioscience by 81.7% during the first quarter. Envestnet Asset Management Inc. now owns 5,900 shares of the company’s stock valued at $291,000 after acquiring an additional 2,653 shares during the last quarter. US Bancorp DE raised its holdings in shares of Twist Bioscience by 11.8% in the first quarter. US Bancorp DE now owns 5,942 shares of the company’s stock worth $295,000 after buying an additional 626 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Twist Bioscience by 81.2% in the first quarter. MetLife Investment Management LLC now owns 29,690 shares of the company’s stock worth $1,466,000 after buying an additional 13,308 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Twist Bioscience by 12.1% during the first quarter. Rhumbline Advisers now owns 56,408 shares of the company’s stock worth $2,785,000 after purchasing an additional 6,110 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Twist Bioscience by 8.3% during the first quarter. BlackRock Inc. now owns 4,692,119 shares of the company’s stock worth $231,696,000 after purchasing an additional 358,217 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.